Jan 22 (Reuters) - Corcept Therapeutics said on Thursday a late-stage trial showed its experimental drug in combination with chemotherapy helped reduce the risk of death in patients with a type of ...

Right after a heart attack, the risk of having another one is very high. This is the most dangerous time for your heart. Blood vessels are still fragile and more likely to form dangerous clots. That’s ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...

Epcoritamab combo reduced the risk of disease progression or death by 79% in the Phase 3 FL trial. Genmab raised its 2025 revenue outlook to $3.5–$3.7 billion after Q2 beat and 19% Y/Y growth. Up Next ...

A combination of two cancer drugs significantly boosts lifespan in mice, according to a new study that may lead to better strategies for longevity. The drugs rapamycin and trametinib given together as ...

While current clinical trials for cardiac regeneration using induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) ...

New research suggests THC’s cognitive drawbacks may be mitigated when combined with a targeted anti-inflammatory drug. Cannabis research has highlighted a scientific paradox. Its best-known ...

In recent years, research into cannabis and its main psychoactive ingredient, Δ⁹-tetrahydrocannabinol (THC), has unearthed ...

Those with prostate cancer that returns after surgery or radiation—and typically face a high risk of the disease spreading and death—could benefit from a new drug combination. A Cedars-Sinai Medical ...

Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one-third of the adult population. This disorder is characterized by the ...

Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in ...